Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 287

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 287
---
,111

        $
        300,986

        Research and development

        1,115,552

        177,904

        Total stock-based compensation expense

        $
        1,958,663

        $
        478,890

Note 14—Commitments and contingencies Lease Commitments – The Company leases facilities under non-cancelable operating leases for the laboratory and offices in Tampa, Florida. The current lease expires in February 2026.Future minimum lease payments under these leases are as follows: 

        Year ending December 31, 2025
         
        $
        172,931

        Year ending December 31, 2026

        43,411

        Interest portion of right of use liability

        (13,800
        )

        Operating lease liabilities
         
        $
        202,542

       Total lease expense was approximately $163,000 and $126,000 for the years ended December 31, 2024 and 2023, respectively.Cash paid for amounts included in the measurement of lease liabilities was approximately $160,000 and $126,000 for the years ended December 31, 2024 and 2023.For the current lease, the weighted-average lease term is 1.25 years and 2.25 years and the weighted average discount rate is 10.0% as of December 31, 2024 and 2023Employment Agreements – In March 2024, the Company signed a consulting agreement with an entity owned by the former CEO and President and paid approximately $243,000 and $555,000 for the years ended December 31, 2024 and 2023.  In May 2023, and amended in March 2024, and in November of 2024, the Company signed employment agreements with the CEO and CFO.Future minimum payments under these employment and consulting agreements are as follows: 

F-24

TUHURA BIOSCIENSES, INC AND SUBSIDIARIESNotes to the consolidated financial statementsFor the years ended December 31, 2024, and 2023  

        Year ending December 31, 2025
         
        $
        949,000

        Year ending December 31, 2026

        874,000

        $
        1,823,000

Note 15—Subsequent eventsSubsequent events – The Company has evaluated subsequent events through March